Newsroom

Takeda’s LIVTENCITY^TM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

Takeda Applied for Selection of “Prime Market”,  Filed Corporate Governance Report with Tokyo Stock Exchange (TSE) in Line with Revised Corporate Governance Code and Published Corporate Governance related Documents on its website

Takeda Announces Acquisition of Own Shares

Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors